AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
/ 5 items
#NKTR↓
New Drug Shows Stronger Hair Regrowth After 1 Year in Severe Alopecia Areata
Nektar drug showed promising hair regrowth in severe alopecia areata after 52 weeks, with good safety and twice-monthly shots.
William Blair Upgrades Nektar on Strong Rezpeg Drug Data
William Blair upgrades Nektar to Outperform following promising long-term data for rezpegaldesleukin in atopic dermatitis treatment with improved safety profile. The results met and in some cases exceeded investor expectations.
Nektar's Alopecia Drug Shows Promise But Raises Concerns
Nektar's (NKTR) rezpegaldesleukin demonstrates hair regrowth in alopecia areata patients but narrowly misses primary endpoint, presenting mixed results as company advances to Phase 3 trials.
Nektar’s Rezpegaldesleukin Shows Efficacy in Phase 2b Atopic Dermatitis Trial
A new medicine, rezpegaldesleukin, shows promise for moderate-to-severe eczema. It boosts special immune cells to rebalance the body and cut inflammation, leading to rapid and deeper symptom relief. It's an FDA Fast Tracked, self-injected treatment.